Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 20/20 | 0.76 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28863222 | 0.90 | CDK8 (0.84) | CDK8CDK7CDK6 | |
| SCHEMBL29996613 | 0.90 | CDK8 (0.84) | CDK8CDK7CDK6 | |
| SCHEMBL28863224 | 0.86 | CDK8 (1.00) | CDK8CDK7CDK6 | |
| SCHEMBL29996405 | 0.86 | CDK8 (1.00) | CDK8CDK7CDK6 | |
| SCHEMBL28863253 | 0.85 | CDK8 (1.00) | CDK8CDK7CDK6 | |
| SCHEMBL29996559 | 0.85 | CDK8 (1.00) | CDK8CDK7CDK6 | |
| SCHEMBL29995607 | 0.85 | CDK8 (0.91) | CDK8CDK7CDK6 | |
| SCHEMBL28863220 | 0.85 | CDK8 (0.91) | CDK8CDK7CDK6 | |
| SCHEMBL14949675 | 0.84 | CDK8 (0.64) | CDK8CDK7CDK6 | |
| SCHEMBL29996371 | 0.84 | CDK8 (0.87) | CDK8CDK7CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2162445-B1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2162445-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008150015-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | CDK8 2998/4885CDK7 2605/4885CDK6 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.